Walleye Trading LLC Sells 6,224 Shares of Structure Therapeutics Inc. (NASDAQ:GPCR)

Walleye Trading LLC decreased its holdings in Structure Therapeutics Inc. (NASDAQ:GPCR) by 42.1% in the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 8,576 shares of the company’s stock after selling 6,224 shares during the period. Walleye Trading LLC’s holdings in Structure Therapeutics were worth $376,000 as of its most recent SEC filing.

Other institutional investors also recently made changes to their positions in the company. Sandia Investment Management LP purchased a new stake in shares of Structure Therapeutics in the 2nd quarter valued at $39,000. Assetmark Inc. boosted its stake in shares of Structure Therapeutics by 120.0% in the 3rd quarter. Assetmark Inc. now owns 1,318 shares of the company’s stock valued at $58,000 after purchasing an additional 719 shares in the last quarter. Quarry LP purchased a new stake in shares of Structure Therapeutics in the 2nd quarter valued at $79,000. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Structure Therapeutics by 60.1% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,784 shares of the company’s stock valued at $158,000 after purchasing an additional 1,420 shares in the last quarter. Finally, Dearborn Partners LLC purchased a new stake in shares of Structure Therapeutics in the 3rd quarter valued at $202,000. Hedge funds and other institutional investors own 91.78% of the company’s stock.

Structure Therapeutics Trading Up 0.9 %

Shares of NASDAQ GPCR opened at $33.55 on Thursday. Structure Therapeutics Inc. has a 12 month low of $26.61 and a 12 month high of $64.45. The firm has a market capitalization of $1.92 billion, a PE ratio of -45.34 and a beta of -3.41. The firm has a fifty day simple moving average of $37.66 and a two-hundred day simple moving average of $39.38.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the stock. JMP Securities cut their price objective on shares of Structure Therapeutics from $91.00 to $86.00 and set a “market outperform” rating for the company in a research note on Friday, August 9th. HC Wainwright assumed coverage on shares of Structure Therapeutics in a research report on Wednesday. They set a “buy” rating and a $80.00 price target for the company. Morgan Stanley assumed coverage on shares of Structure Therapeutics in a research report on Monday, September 23rd. They set an “overweight” rating and a $118.00 price target for the company. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $65.00 price target on shares of Structure Therapeutics in a research report on Monday, September 23rd. Seven analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $85.67.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.